within Pharmacolibrary.Drugs.ATC.P;

model P01AX11
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.7,
    Cl             = 10.9 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 500 / 1000000,
    adminCount     = 1,
    Vd             = 0.00138,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.011000000000000001,
    Tlag           = 18.0
  );

  annotation(Documentation(
    info ="<html><body><p>Nitazoxanide is a synthetic nitrothiazolyl-salicylamide derivative with broad-spectrum antiparasitic and antiviral activity. Originally developed and approved for treating protozoal infections such as Giardia lamblia and Cryptosporidium parvum, nitazoxanide is currently approved in multiple regions for the treatment of infectious diarrhea caused by these organisms in both children and adults.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for healthy adult volunteers after a single oral administration of 500 mg nitazoxanide tablet. Parameters are for its active circulating metabolite, tizoxanide.</p><h4>References</h4><ol><li><p>Zhang, C, et al., &amp; Zhao, H (2024). Pharmacokinetics of Nitazoxanide Dry Suspensions After Single Oral Doses in Healthy Subjects: Food Effects Evaluation and Bioequivalence Study. <i>Clinical pharmacology in drug development</i> 13(7) 748–754. DOI:<a href=&quot;https://doi.org/10.1002/cpdd.1402&quot;>10.1002/cpdd.1402</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/38573189/&quot;>https://pubmed.ncbi.nlm.nih.gov/38573189</a></p></li><li><p>Stockis, A, et al., &amp; Rossignol, JF (1996). Pharmacokinetics of nitazoxanide after single oral dose administration in 6 healthy volunteers. <i>International journal of clinical pharmacology and therapeutics</i> 34(8) 349–351. PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/8864798/&quot;>https://pubmed.ncbi.nlm.nih.gov/8864798</a></p></li><li><p>Li, F, et al., &amp; Dong, D (2022). Anthelmintics nitazoxanide protects against experimental hyperlipidemia and hepatic steatosis in hamsters and mice. <i>Acta pharmaceutica Sinica. B</i> 12(3) 1322–1338. DOI:<a href=&quot;https://doi.org/10.1016/j.apsb.2021.09.009&quot;>10.1016/j.apsb.2021.09.009</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/35530137/&quot;>https://pubmed.ncbi.nlm.nih.gov/35530137</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end P01AX11;
